Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies

Abstract

Despite the evidence indicating that long-acting injectable antipsychotics (LAIAs) are effective and safe options for the treatment of schizophrenia, various factors related to patients, clinicians and/or health policy makers have impeded their use. Solutions to overcoming these barriers include better communication of LAIA options, improved convenience and cost assistance, and guideline updates. Together, these strategies may result in more widespread prescribing of LAIAs for the treatment of schizophrenia, thereby facilitating improved patient outcomes.